Inhibikase
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Inhibikase and other ETFs, options, and stocks.About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases.
CEOMark T. Iwicki
CEOMark T. Iwicki
Employees16
Employees16
HeadquartersWilmington, Delaware
HeadquartersWilmington, Delaware
Founded2008
Founded2008
Employees16
Employees16
IKT Key Statistics
Market cap140.46M
Market cap140.46M
Price-Earnings ratio-1.74
Price-Earnings ratio-1.74
Dividend yield—
Dividend yield—
Average volume106.58K
Average volume106.58K
High today$1.90
High today$1.90
Low today$1.69
Low today$1.69
Open price$1.70
Open price$1.70
Volume210.70K
Volume210.70K
52 Week high$4.20
52 Week high$4.20
52 Week low$1.12
52 Week low$1.12
People also own
Based on the portfolios of people who own IKT. This list is generated using Robinhood data, and it’s not a recommendation.